These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19005025)

  • 1. Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans.
    Sarfo FS; Phillips RO; Ampadu E; Sarpong F; Adentwe E; Wansbrough-Jones M
    Clin Vaccine Immunol; 2009 Jan; 16(1):61-5. PubMed ID: 19005025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine response to antigen stimulation of whole blood from patients with Mycobacterium ulcerans disease compared to that from patients with tuberculosis.
    Phillips R; Horsfield C; Kuijper S; Sarfo SF; Obeng-Baah J; Etuaful S; Nyamekye B; Awuah P; Nyarko KM; Osei-Sarpong F; Lucas S; Kolk AH; Wansbrough-Jones M
    Clin Vaccine Immunol; 2006 Feb; 13(2):253-7. PubMed ID: 16467334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.
    Ruf MT; Schütte D; Chauffour A; Jarlier V; Ji B; Pluschke G
    Antimicrob Agents Chemother; 2012 Feb; 56(2):687-96. PubMed ID: 22143518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of rifampicin-streptomycin for treatment of Buruli ulcer: a systematic review.
    Tanywe A; Fernandez RS
    JBI Database System Rev Implement Rep; 2017 Jan; 15(1):119-139. PubMed ID: 28085731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease).
    Chauty A; Ardant MF; Adeye A; Euverte H; Guédénon A; Johnson C; Aubry J; Nuermberger E; Grosset J
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4029-35. PubMed ID: 17526760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial.
    Nienhuis WA; Stienstra Y; Thompson WA; Awuah PC; Abass KM; Tuah W; Awua-Boateng NY; Ampadu EO; Siegmund V; Schouten JP; Adjei O; Bretzel G; van der Werf TS
    Lancet; 2010 Feb; 375(9715):664-72. PubMed ID: 20137805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease).
    Kibadi K; Boelaert M; Fraga AG; Kayinua M; Longatto-Filho A; Minuku JB; Mputu-Yamba JB; Muyembe-Tamfum JJ; Pedrosa J; Roux JJ; Meyers WM; Portaels F
    PLoS Negl Trop Dis; 2010 Jul; 4(7):e736. PubMed ID: 20625556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.
    Etuaful S; Carbonnelle B; Grosset J; Lucas S; Horsfield C; Phillips R; Evans M; Ofori-Adjei D; Klustse E; Owusu-Boateng J; Amedofu GK; Awuah P; Ampadu E; Amofah G; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3182-6. PubMed ID: 16048922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions.
    Schütte D; Umboock A; Pluschke G
    Br J Dermatol; 2009 Feb; 160(2):273-83. PubMed ID: 19016694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.
    Sarfo FS; Phillips R; Asiedu K; Ampadu E; Bobi N; Adentwe E; Lartey A; Tetteh I; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3678-85. PubMed ID: 20566765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.
    Phillips RO; Sarfo FS; Abass MK; Abotsi J; Wilson T; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014; 58(2):1161-6. PubMed ID: 24323473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease.
    Prévot G; Bourreau E; Pascalis H; Pradinaud R; Tanghe A; Huygen K; Launois P
    Infect Immun; 2004 Feb; 72(2):958-65. PubMed ID: 14742541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?
    Converse PJ; Nuermberger EL; Almeida DV; Grosset JH
    Future Microbiol; 2011 Oct; 6(10):1185-98. PubMed ID: 22004037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
    Sarpong-Duah M; Frimpong M; Beissner M; Saar M; Laing K; Sarpong F; Loglo AD; Abass KM; Frempong M; Sarfo FS; Bretzel G; Wansbrough-Jones M; Phillips RO
    PLoS Negl Trop Dis; 2017 Jul; 11(7):e0005695. PubMed ID: 28671942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection?
    Ruf MT; Chauty A; Adeye A; Ardant MF; Koussemou H; Johnson RC; Pluschke G
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1252. PubMed ID: 21829740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection.
    Zhang T; Li SY; Converse PJ; Almeida DV; Grosset JH; Nuermberger EL
    Antimicrob Agents Chemother; 2011 Jan; 55(1):56-61. PubMed ID: 21078940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study.
    O'Brien DP; McDonald A; Callan P; Robson M; Friedman ND; Hughes A; Holten I; Walton A; Athan E
    PLoS Negl Trop Dis; 2012 Jan; 6(1):e1473. PubMed ID: 22272368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compliance with antimicrobial therapy for buruli ulcer.
    Klis S; Kingma R; Tuah W; Stienstra Y; van der Werf TS
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6340. PubMed ID: 25225342
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to "compliance with antimicrobial therapy for buruli ulcer".
    Phillips RO; Sarfo FS; Abass MK; Frimpong M; Ampadu E; Forson M; Amoako YA; Thompson W; Asiedu K; Wansbrough-Jones M
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6341. PubMed ID: 25225343
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical outcomes of Ghanaian Buruli ulcer patients who defaulted from antimicrobial therapy.
    Klis S; Kingma RA; Tuah W; van der Werf TS; Stienstra Y
    Trop Med Int Health; 2016 Sep; 21(9):1191-6. PubMed ID: 27456068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.